No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for ALX Oncology Holdings Inc. (ALXO) stock was $1.16 as of Oct 6, 2026, 10:35 AM EDT, down 4.55% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -44.3% · 3-year avg -43.1%/yr · 5-year avg -56.1%/yr
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.15
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.11
vs Estimate
$-0.16
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALXO | $155.42M | $1.16 | -4.55% | -44.34% | -56.07% | N/A | N/A |
| 2MENS | $156.62M | $2.06 | +0.49% | -95.66% | N/A | N/A | vs ALXO |
| 3NERV | $154.21M | $3.31 | -0.30% | +57.75% | -22.14% | -29.77% | vs ALXO |
| 4INGN | $157.44M | $5.82 | -2.10% | -31.21% | -32.83% | -20.74% | vs ALXO |
| 5AVXL | $152.12M | $1.64 | -0.21% | -83.29% | -37.74% | -7.93% | vs ALXO |
| 6CDXS | $151.66M | $1.41 | +1.44% | -45.12% | -44.64% | -11.05% | vs ALXO |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$4.60
+298.3% upside
Low
$4.00
Current
$1.16
High
$6.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.14 | $-0.13 | $-0.11 | 4 |
| Quarter ending Dec 2026 | $-0.15 | $-0.13 | $-0.11 | 4 |
| Quarter ending Mar 2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Quarter ending Jun 2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.60 | $-0.56 | $-0.52 | 3 |
| FY 2027 | $-0.65 | $-0.55 | $-0.49 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.60M | $4.60M | $4.60M | 5 |
| FY 2027 | $5.35M | $5.35M | $5.35M | 5 |
